Part of University of Pennsylvania
Clinical Trials
457
70 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
49
10.7%
Completed
247
54.0%
Enrolling By Invitation
13
2.8%
Not yet recruiting
8
1.8%
Recruiting
66
14.4%
Terminated
46
10.1%
Unknown
1
0.2%
Withdrawn
27
5.9%
No approval data available
- A cross-sectional analysis of Google and YouTube content found only 31% of webpages and 19% of videos on AI and cancer care were patient-facing and relevant. - Median readability of webpages was at college level, far exceeding the AMA/NIH-recommended 6th–8th grade reading level for consumer health information. - Fewer than 20% of resources mentioned AI misinformation or hallucination risks, and only 33% of webpages and 23% of videos were rated high quality. - Researchers call on national oncology organizations and advocacy groups to develop accessible, plain-language resources that address patient safety in AI use.
- Five-year follow-up data from the phase 3 KEYNOTE-564 study demonstrate that adjuvant pembrolizumab continues to improve disease-free survival and overall survival compared to placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence. - The immunotherapy showed consistent benefits across all prespecified subgroups, including varying risk categories and patients with sarcomatoid features, with median disease-free survival not reached versus 68.3 months with placebo. - Real-world data from the ARON-1 study confirm pembrolizumab's effectiveness in clinical practice, with 2-year overall survival and disease-free survival rates of 95% and 69%, respectively. - Long-term safety profile remains stable with no new serious toxicities emerging beyond three years of treatment.
- A phase 2a trial of CAN-2409 viral immunotherapy showed median overall survival of 24.5 months in 46 patients with advanced NSCLC who failed immune checkpoint inhibitor therapy. - Patients with non-squamous histology demonstrated significantly longer survival than those with squamous histology (25.4 vs. 13.3 months), linked to increased cytotoxic T-cell infiltration. - The treatment triggered systemic immune activation with abscopal responses in 69% of patients with multiple lesions, indicating robust anti-tumor effects beyond the injection site. - CAN-2409 maintained a favorable safety profile throughout extended follow-up, supporting advancement to larger randomized controlled trials.
- A first-of-its-kind clinical trial demonstrated that repurposed cancer drugs can effectively target dormant breast cancer cells, clearing them in 80% of participants and potentially preventing cancer recurrence. - The study enrolled 51 breast cancer survivors and achieved remarkable outcomes with three-year survival rates above 90% for single-drug therapy and 100% for combination therapy. - Researchers identified dormant tumor cells in bone marrow that can reactivate years or decades later, representing a critical window for intervention before metastatic disease develops. - The findings offer hope for transforming breast cancer survivorship from a "wait and see" approach to active prevention of incurable relapse through targeted treatment of minimal residual disease.
- The phase 2/3 ECOG-ACRIN EA2174 trial showed that adding nivolumab to neoadjuvant chemoradiation did not significantly improve pathologic complete response (pCR) rates in patients with locoregional esophageal adenocarcinoma. - The pCR rate with nivolumab plus chemoradiation was 24.8% compared to 21.0% with chemoradiation alone (P = .27), indicating no statistically significant difference between the two treatment arms. - The trial's findings suggest that incorporating immune checkpoint inhibitors into neoadjuvant chemotherapy and radiation regimens may not provide additional efficacy for these patients. - Ongoing analyses of tissue and blood samples from the trial participants aim to identify potential biomarkers that could predict responsiveness to immune checkpoint inhibitor therapy.
